Table 2.
Treatment regimens for HIV-associated ITP and responses achieved.
| Treatment | Dose | N | Bleeding (%) | R + CR (%) | CR (%) | Median time to R in days (range) | Relapse (%) |
|---|---|---|---|---|---|---|---|
| IVIG | 1 g/kg/day × 2 days | 7 | 6 (86) | 5 (71) | 4 (57) | 4 (3–9) | 6 (86) |
| Anti-D | 2.4–4 mg | 7 | 2 (29) | 6 (86) | 0 (0) | 14 (1–61) | 4 (57) |
| Prednisone | 50–85 mg daily | 4 | 2 (50) | 4 (100) | 1 (25) | 4.5 (3–13) | 3 (75) |
| HAART alone | *See footnote | 4 | 1 (25) | 3 (75) | 1 (25) | 267 (1–1379) | 3 (75) |
| IVIG + | 1 g/kg/day × 2 days | 5 | 4 (80) | 5 (100) | 3 (60) | 11 (3–16) | 3 (60) |
| Prednisone | 50–70 mg | ||||||
| Anti-D + | 1.3 mg | 1 | 1 (100) | 1 (100) | 0 (0) | 22 | 1 (100) |
| Prednisone | 40 mg daily | ||||||
| HAART + | **See footnote | 9 | 5 (56) | 8 (89) | 5 (56) | 13.5 (3–22) | 4 (44) |
| Other therapy | |||||||
| None | 3 | 0 (0) | 2 (67) | 2 (67) | 696 (26–3192) | 2 (67) |
*HAART was 1 nucleoside analog (NA), 1 protease inhibitor, and either a 2nd NA or a nonnucleoside reverse transcription inhibitor.
**Other therapy was IVIG, prednisone, or anti-D in the doses listed above. Patients in this group were also included in the groups above with patients who received the respective therapies without HAART.